새턱 랩스(STTK)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $6.06 (+3.59%), 시가총액 $0.48B, 52주 최저~최고 $0.73 ~ $7.88.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an onc
새턱 랩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
새턱 랩스의 현재 주가는 $6.06 (+3.59%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
새턱 랩스의 시가총액은 약 $0.48B입니다.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company d